Aortic valve replacement now happens more commonly via TAVR than through surgery, or SAVR. Here's everything you need to know about the TAVR procedure.
Transcatheter aortic valve replacement (TAVR), also referred to as transcatheter aortic valve implantation (TAVI), is a procedure that replaces your diseased aortic valve with a man-made valve.
Endovascular repair of the aorta....
This minimally invasive procedure to replace a narrowed aortic valve is an option to open-heart valve surgery. Learn about the benefits and risks of TAVR.
Complete explanation of the TAVR Procedure for aortic stenosis patients with videos, success stories and leading TAVR doctors.
Proposal would expand access to TAVR in Medicare by modernizing the requirements that providers must meet to perform the cardiac procedure under Coverage with Evidence Development
Know Your Doctor Dr. Mayur Jain Dr. Mayur Jain is an interventional cardiologist who is very good at preventive cardiology!! A rarity !Most important skill that the doctor thinks he has is ‘he knows where to stop!’ He is known for his genuine advice and exceptionally fine skills at procedures avoiding most of the complications. […]
Dr. Ahmed answers all your TAVR questions, including a definition of TAVR, how it compares to open heart surgery, possible complications, and more.
Receive international quality medical attention, with the best specialists in Mexico.
The HLT Meridian TAVR Valve System is designed to overcome some of the challenges of current FDA-cleared TAVR devices
Watch this video to learn how transcatheter aortic valve replacement procedures are advancing the treatment of aortic stenosis with Dr. Alan Malki, surgeon.
In early November, the U.S. Food and Drug Administration approved the first transcatheter valve for the treatment of inoperable aortic stenosis, the Sapien valve (Edwards Lifesciences). Clearly, this is one of the most exciting advances in interventional cardiology in the last decade. The procedure is called the transaortic valve replacement (TAVR) or implant (TAVI) and is usually done percutaneously via the femoral arteries or may be performed by a transapical surgical approach. from Cath Lab Digest.
Results presented at SCAI 2018 show novel technology could reduce risks paravalvular leaks
Andrew Weintraub, M.D., FACC, associate director, of the Interventional Cardiology and Vascular Center, medical director of the Vascular and Structural Heart Center, Tufts Medical Center, discusses the use of temporary pacing in transcatheter aortic valve replacement (TAVR) patients. Implantation of TAVR valves can cause pressure from the valve against the septal wall of the heart, causing conduction delays. These delays do not necessarily mean the patient needs a permanent pacemaker. Instead, Tufts Medical Center uses temporary pacing leads, a small catheter with two electrodes, placed in the right ventricle of the heart through a vein in the groin or neck. The lead is then connected to an external pacemaker allowing a physician to monitor and control a patient’s heart rate for up to several days. The center uses the BioTrace Medical Tempo Lead, which incorporates a novel active fixation mechanism, bipolar electrodes and a soft tip. Stabilizers provide secure fixation and maintain stable pace capture. An elastomeric balloon may be inflated to aid passage of the lead through the venous vasculature and into the right ventricle, and aids in wall apposition during deployment of the stabilizers. This design helps secure and stabilize the cardiac pacing lead with the goal of reducing complications and allowing patients to ambulate sooner after procedures. Related Content: VIDEO: Overview of the TAVR Program at Tufts Medical Center — Interview with Andrew Weintraub, M.D. VIDEO: The Expansion of TAVR Following the FDA Clearing its Use in All Patients — Interview with Torsten Vahl, M.D. VIDEO: Overview of the Structural Heart Program at Tufts Medical Center — Interview with Charles D. Resor, M.D., Find more content on Tufts Medical Center
Get critical information about aortic valve debris and stroke risk of transcatheter aortic valve replacement (TAVR) & SAVR from Dr. Craig Smith, heart surgeon.
Oral anticoagulation reduces clot formation around the implanted valve with no increased bleeding risk
Addition of FDA-cleared Sentinel Cerebral Embolic Protection System will expand Boston's structural heart offerings
Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University Hospital, Stockholm, Sweden, explains the latest data on the Boston Scientific Acurate neo2 transcatheter aortic valve replacement (TAVR) system. It demonstrated positive procedural performance, including low rates of paravalvular leak (PVL) and permanent pacemaker implementation, in data presented in late-breaking sessions at the EuroPCR 2021 congress. These areas improved from the trials using the first generation valve. The Acurate neo2 valve design enhancements include a 60% larger outer sealing skirt to better conform to challenging anatomies to better minimized PVL. Boston Scientific said the ACURATE IDE pivotal U.S. trial is currently enrolling patients to evaluate the safety of the ACURATE neo2 Aortic Valve System. In April 2021, the company received FDA approval to modify the trial design to study patients with severe, symptomatic aortic stenosis who are at low risk for open-heart surgery, in addition to those at intermediate, high and extreme risk. Related Acurate neo TAVR Valve Content: Acurate neo2 TAVR Valve Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates Boston Scientific Makes a Comeback With Positive Clinical Data for its Second Iteration Acurate neo2 TAVR Valve TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States Boston Scientific Launches Acurate neo2 Transcatheter Aortic Valve System in Europe New Acurate neo Self-expanding TAVR Device Does Not Meet Non-Inferiority Compared to Sapien 3 Acurate neo TAVR Valve Fails to Meet Noninferiority With Medtronic CoreValve Evolut VIDEO: Interventional Structural Heart Advances Are Rapidly Expanding — Interview with Juan F. Granada, M.D. Boston Scientific to Acquire TAVR Maker Symetis
Valve now indicated for all patients diagnosed with severe symptomatic aortic stenosis
The FDA approved TAVR (transcatheter aortic valve replacement), a minimally invasive procedure, for severe aortic stenosis patients at risk for heart surgery
